We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.
作者：Sun Hwa, Kim；Sin Gon, Kim；Doo Man, Kim；Jeong-Taek, Woo；Hak Chul, Jang；Choon Hee, Chung；Kyung Soo, Ko；Jeong Hyun, Park；Yong Soo, Park；Sang Jin, Kim；Dong Seop, Choi
来源：Diabetes research and clinical practice 2015 年 110卷 3期
